This new indication marks the second FDA approval for sacituzumab govitecan (Trodelvy, Immunomedics) and was based on the phase 2, single-arm TROPHY-U-01 main efficacy endpoints in objective response rate (ORR) and duration of response (DOR). With a relative 5-year survival rate of 5.5%, this is a significant advancement for patients with metastatic urothelial cancer (mUC), the most common type of bladder cancer.

The ECOG-ACRIN E1412 study demonstrated a potential clinical benefit of adding lenalidomide to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) (R2CHOP) in newly diagnosed patients regardless of cell-of-origin (COO) and in patients with activated b-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL). Although the results are not practice changing, they support further studies of lenalidomide and/or novel lenalidomide analogues in frontline therapy of DLBCL.

The first biologic was approved in 1982, and since then, have become one of the fastest-growing segments of the US pharmaceutical market. Biologics are complex therapies used to treat a wide variety of conditions – conditions that are often untreatable by any other drug – and physicians should be up to speed on these four classes of biologic agents, which are used to treat cancer or inflammatory disease.

According to the American Institute for Cancer Research, a diet filled with a variety of vegetables, fruits, whole grains, beans, and other plant foods helps lower risk for many cancers, thanks to their bioactive compounds. Things like bergamottin. Isothiocyanates. Polyphenols. Continue reading to discover five foods that have the potential to fight cancer, including pancreatic, skin, and more.

“You are what you eat,” right? Well, according to the National Institute on Aging (NIA), what you put into your mouth could be influencing your cognitive health and performance. A healthy diet of fruits, vegetables, lean meats, fish, poultry, low-fat/nonfat dairy products, and whole grains is essential, as is limiting fats, sugars, and salt. But here is the best of the best when it comes to boosting the brain.

The approval of the new cetuximab (Erbitux) dosage – 500 mg/m2 as a two-hour IV infusion every two weeks – was based on population pharmacokinetic (PK) modeling analyses and provides an alternative option to the previously approved weekly dose. Cetuximab can be dosed alone or in combination with chemotherapy.